RUNX1T1 and colorectal carcinoma: RUNX1T1 is collectively viewed as a biomarker for primary pancreatic endocrine tumors (PETs), breast cancer, and colorectal cancer (CRC) and a strong indicator of patient prognosis [51, 54, 55].